Using a genetic approach, we demonstrated that ablation of TCPTP in the pancreas ameliorated the course of AP as shown by the reduced serum amylase and lipase activities, decreased pancreatic TNFα, IL-1β and IL-6 expression and decreased serum levels of TNFα and IL-6. The gene discussed is PTPN2; the disease is alkaline phosphatase measurement.